NASD · Healthcare · Biotechnology · USA
Vertex Pharmaceuticals Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Vertex Pharmaceuticals is a global biotechnology company that creates medicines for serious diseases in specialty markets. The company has approved treatments for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. It sells its medicines through specialty pharmacies, distributors, and wholesalers to patients, healthcare providers, hospitals, and authorized treatment centers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Vertex Pharmaceuticals Inc stock.
Overvalued: intrinsic value $381.90 per share, market price $501.95, margin of safety -31.4% (as of 2026-10-19).
Discounting its cash flows at 7.5% (average of 3 methods) values the shares at $381.90; the price of $501.95 is 31% above that value, and 82% of that value comes from beyond year five.
Leak Score: 54/100 on 11 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
42 more in this industry show a wider margin of safety.
VRTX is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 7.5% (average of 3 methods) values the shares at $381.90; the price of $501.95 is 31% above that value, and 82% of that value comes from beyond year five.
$381.90 per share (as of the 2026-10-19 close), against a market price of $501.95. That is a margin of safety of -31.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for more growth than the company has delivered. It needs the future to beat the past. Yearly sales growth the price needs: 22.6%. Yearly sales growth it has sustained: 11.7%.
54 out of 100, which we rate "Weak Signal", on 11 of 12 value investing signals.